- Conditions
- RSV Infections
- Interventions
- Not listed
- Lead sponsor
- Shionogi
- Industry
- Eligibility
- Up to 36 Months
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 2
- States / cities
- Syracuse, New York • Seattle, Washington
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 145–168
of 201
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Respiratory Syncytial Virus Infections
- Interventions
- JNJ-53718678, Placebo
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 28 Days to 3 Years
- Enrollment
- 246 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 14
- States / cities
- Madera, California • Ventura, California • Aurora, Colorado + 11 more
- Conditions
- Pharmacokinetics, Healthy Volunteers
- Interventions
- BTA-C585 oral capsules, BTA-C585 matching placebo
- Drug
- Lead sponsor
- Biota Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 36 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2016
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Respiratory Syncytial Virus (RSV)
- Interventions
- RSVpreF MDV, RSVpreF SDV
- Biological
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 49 Years · Female only
- Enrollment
- 453 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024
- U.S. locations
- 6
- States / cities
- South Miami, Florida • Stockbridge, Georgia • Idaho Falls, Idaho + 3 more
- Conditions
- Respiratory Syncytial Viruses, Respiratory Tract Infections
- Interventions
- Ad26.RSV.FA2, Ad35.RSV.FA2, Placebo
- Biological · Drug
- Lead sponsor
- Crucell Holland BV
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 34 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2016
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Hematologic Malignancies, Hematopoietic Stem Cell Transplant (HSCT)
- Interventions
- PUL-042, Placebo
- Drug
- Lead sponsor
- Pulmotect, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 12
- States / cities
- Duarte, California • Atlanta, Georgia • Baltimore, Maryland + 9 more
- Conditions
- Respiratory Syncytial Virus Infections
- Interventions
- RSVPreF3 OA investigational vaccine
- Biological
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 60 Years and older
- Enrollment
- 770 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2022
- U.S. locations
- 9
- States / cities
- Waterbury, Connecticut • Brooksville, Florida • Immokalee, Florida + 6 more
- Conditions
- Respiratory Syncytial Virus Infections
- Interventions
- RSV F vaccine with adjuvant, Formulation buffer
- Biological
- Lead sponsor
- Novavax
- Industry
- Eligibility
- 18 Years to 40 Years · Female only
- Enrollment
- 4,636 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2019
- U.S. locations
- 49
- States / cities
- Birmingham, Alabama • Cullman, Alabama • Fort Defiance, Arizona + 43 more
- Conditions
- Respiratory Syncytial Virus Infections
- Interventions
- CodaVax-RSV, Normal Saline
- Biological
- Lead sponsor
- Codagenix, Inc
- Industry
- Eligibility
- 6 Months to 5 Years
- Enrollment
- 41 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2026
- U.S. locations
- 4
- States / cities
- Lincoln, Nebraska • Omaha, Nebraska • Providence, Rhode Island + 1 more
- Conditions
- Respiratory Syncytial Viruses, Respiratory Syncytial Virus Infections
- Interventions
- RSVPreF3 OA investigational vaccine, HZ/su vaccine
- Biological
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 530 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2024
- U.S. locations
- 11
- States / cities
- Daphne, Alabama • Tempe, Arizona • Corte Madera, California + 8 more
- Conditions
- Respiratory Tract Infection
- Interventions
- Formulation A, Formulation B, Formulation C, Placebo
- Biological
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 65 Years to 85 Years
- Enrollment
- 317 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2020
- U.S. locations
- 4
- States / cities
- South Miami, Florida • Peoria, Illinois • Fremont, Nebraska + 1 more
- Conditions
- Respiratory Syncytial Virus Infection
- Interventions
- Abrysvo, Beyfortus
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 45 Years · Female only
- Enrollment
- 181 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2026
- U.S. locations
- 8
- States / cities
- Atlanta, Georgia • Baltimore, Maryland • New York, New York + 5 more
- Conditions
- Respiratory Syncytial Virus
- Interventions
- mRNA-1345
- Biological
- Lead sponsor
- ModernaTX, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,153 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 32
- States / cities
- Glendale, Arizona • Phoenix, Arizona • Tempe, Arizona + 28 more
- Conditions
- RSV Infection
- Interventions
- Obeldesivir, Obeldesivir Placebo
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 121
- States / cities
- Birmingham, Alabama • Cullman, Alabama • Guntersville, Alabama + 81 more
- Conditions
- Respiratory Syncytial Viruses, Lower Respiratory Tract Disease
- Interventions
- Adenovirus serotype 26 (Ad26)-based respiratory syncytial virus (RSV). preF, Placebo
- Biological
- Lead sponsor
- Janssen Vaccines & Prevention B.V.
- Industry
- Eligibility
- 60 Years and older
- Enrollment
- 25,236 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2023
- U.S. locations
- 156
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 126 more
- Conditions
- Healthy
- Interventions
- MEDI-534
- Biological
- Lead sponsor
- MedImmune LLC
- Industry
- Eligibility
- 1 Year to 9 Years
- Enrollment
- 120 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2006 – 2007
- U.S. locations
- 12
- States / cities
- Fountain Valley, California • Shawnee, Kansas • Topeka, Kansas + 9 more
- Conditions
- Respiratory Syncytial Virus Infections
- Interventions
- MEDI8897, Placebo
- Drug
- Lead sponsor
- MedImmune LLC
- Industry
- Eligibility
- Up to 365 Days
- Enrollment
- 1,453 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2018
- U.S. locations
- 60
- States / cities
- Birmingham, Alabama • Anaheim, California • Downey, California + 53 more
- Conditions
- Respiratory Syncytial Virus Infections
- Interventions
- Adjuvanted RSVPreF3 vaccine
- Biological
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 168 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 7
- States / cities
- Lexington, Kentucky • St Louis, Missouri • Omaha, Nebraska + 3 more
- Conditions
- Respiratory Syncytial Virus Infections
- Interventions
- D46cpΔM2-2 vaccine, Placebo
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 6 Months to 60 Months
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2018
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Respiratory Syncytial Virus
- Interventions
- mRNA-1345
- Biological
- Lead sponsor
- ModernaTX, Inc.
- Industry
- Eligibility
- 60 Years and older
- Enrollment
- 507 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2026
- U.S. locations
- 11
- States / cities
- Denver, Colorado • Hialeah, Florida • Savannah, Georgia + 8 more
- Conditions
- Respiratory Syncytial Virus Infections
- Interventions
- RSVPreF3 OA Investigational Vaccine
- Biological
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 386 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2025
- U.S. locations
- 10
- States / cities
- Phoenix, Arizona • Chicago, Illinois • Lexington, Kentucky + 6 more
- Conditions
- RSV Infection
- Interventions
- Obeldesivir, Obeldesivir Placebo
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- Up to 5 Years
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025
- U.S. locations
- 41
- States / cities
- Birmingham, Alabama • Oneonta, Alabama • Phoenix, Arizona + 33 more
- Conditions
- Respiratory Syncytial Virus Infection Prevention
- Interventions
- Ad26.RSV.preF-based Vaccine, Placebo
- Biological · Other
- Lead sponsor
- Janssen Vaccines & Prevention B.V.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,124 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2022
- U.S. locations
- 7
- States / cities
- Coral Gables, Florida • Miami, Florida • El Dorado, Kansas + 4 more
- Conditions
- Respiratory Syncytial Virus Infections
- Interventions
- GSK3888550A RSV Maternal vaccine formulation 1, GSK3888550A RSV Maternal vaccine formulation 2, GSK3888550A RSV Maternal vaccine formulation 3, Placebo (Normal Saline)
- Biological · Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 45 Years · Female only
- Enrollment
- 502 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2019
- U.S. locations
- 2
- States / cities
- Lenexa, Kansas • Rochester, New York